pharmaphorum November 25, 2024
The FDA has approved BridgeBio Pharma’s acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market showdown with its larger rival Pfizer.
Acoramidis has been cleared under the Attruby brand name as an oral therapy to reduce cardiovascular death and cardiovascular-related hospitalisation in adults with ATTR-CM, a progressive disease that leads to heart failure and death.
The labelling puts it in direct contention with Pfizer’s blockbuster Vyndamax/Vyndaqel/Vynmac franchise – based on tafamidis – which has been approved for ATTR-CM since 2019 and is also used to treat polyneuropathy associated with ATTR (ATTR-PN).
ATTR is characterised by the formation of amyloid fibril deposits in tissues and organs – in the heart in the case of patients with cardiomyopathy...
Today's Sponsors
Today's Sponsor